A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer

Primary \- to determine the safety, toxicity, and Maximum Tolerated Dose (MTD) of autologous dendritic cell-adenovirus chemokine (C-C motif) ligand 21 (CCL21) vaccine administered as an intratumoral injection in treating patients with stage IIIB, IV, or recurrent non-small cell lung cancer Secondary * to determine the biologic and clinical responses to therapy * to determine treatment-related toxicity using the NCI Common Toxicity Criteria * to identify the maximum tolerated dose (MTD) * to monitor patients for evidence of autologous dendritic cell-adenovirus CCL21 vaccine-induced cytokines and antigen-specific immune responses * to detect immune responses to tumor-associated antigens and vector * to assess patients for objective signs of tumor regression (RECIST criteria)